10-K: P3 Health Partners Faces Going Concern Doubt Amidst Losses

P3 Health Partners Inc. reports continued net losses and substantial doubt about its ability to continue as a going concern, despite efforts to raise capital and strategic adjustments.

Summary

• P3 Health Partners Inc. reported a net loss of $323.1 million for the fiscal year ended December 31, 2025, an increase from $310.4 million in 2024.
• The company has an accumulated deficit of $651.1 million as of December 31, 2025.
• Management has identified substantial doubt about the company's ability to continue as a going concern within one year from the filing date, a conclusion echoed by its independent auditors.
• Total operating revenue decreased by 3% to $1,459.1 million in 2025 from $1,500.5 million in 2024, primarily due to a 4% decrease in capitated revenue.
• At-risk membership declined by 7% from 126,000 in 2024 to 116,100 in 2025, driven by the strategic termination of underperforming payor contracts and affiliate providers.
• The company used $91.2 million in cash for operating activities in 2025, an improvement from $110.1 million in 2024.
• Outstanding indebtedness totaled $336.7 million as of December 31, 2025, with $45.0 million classified as current.
• Unpaid claims amounted to $287.8 million as of December 31, 2025.
• A 1-for-50 reverse stock split was effected on April 11, 2025, to meet Nasdaq bid price requirements.
• The company received a Nasdaq deficiency letter on November 12, 2025, for not maintaining minimum stockholders' equity of $2.5 million, with an extension granted until May 20, 2026, to regain compliance.
• P3 formed P3 Commonwealth Innovation MSO, LLC in November 2025, holding an 80% interest, to manage accountable care organization programs.
• The company's physician retention rate was over 88% for the year ended December 31, 2025.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as very negative due to the explicit 'substantial doubt about ability to continue as a going concern' statement, persistent net losses, significant debt, and declining revenue and at-risk membership, despite efforts to raise capital and strategic adjustments.

Positives

• Net cash used in operating activities improved to $91.2 million in 2025 from $110.1 million in 2024.
• Corporate, general and administrative expenses decreased by 6% to $106.3 million in 2025, primarily due to an 11% reduction in headcount.
• The company maintained a physician retention rate of over 88% in its affiliate provider network for 2025.
• The formation of P3 Commonwealth Innovation MSO, LLC with an 80% ownership stake positions the company for future growth in ACO programs.
• The company successfully remediated material weaknesses in its internal control over financial reporting as of December 31, 2024.

Negatives

• The company reported a net loss of $323.1 million in 2025, an increase from the $310.4 million loss in 2024.
• An accumulated deficit of $651.1 million as of December 31, 2025, indicates a history of significant losses.
• Management and independent auditors have expressed substantial doubt about the company's ability to continue as a going concern.
• Total operating revenue decreased by 3% year-over-year, primarily due to a 4% decline in capitated revenue.
• At-risk membership decreased by 7% in 2025, attributed to the strategic termination of underperforming contracts.
• Outstanding indebtedness is substantial at $336.7 million, with a significant portion ($45.0 million) due within one year.
• The company has a working capital deficit of $412.2 million and a capital deficiency of $155.2 million as of December 31, 2025.
• Interest expense, net, increased by 148% to $55.0 million in 2025, largely due to increased principal amounts on unsecured promissory notes.
• The company received a Nasdaq deficiency letter for failing to maintain minimum stockholders' equity, risking delisting if compliance is not restored by May 20, 2026.
• Medcore HP, a subsidiary, was non-compliant with California's tangible net equity requirement as of December 31, 2025, and faces a corrective action plan and a $150,000 administrative penalty from August 2024.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern.
• The company requires additional capital to fund operations and growth, with no assurance of timely or satisfactory financing.
• A history of net losses and expectation of continued losses, with no guarantee of achieving or maintaining profitability.
• Risk of not maintaining compliance with debt covenants, which could lead to an event of default and accelerated debt repayment.
• The company's relatively limited operating history makes future prospects and challenges difficult to evaluate.
• A significant portion of assets consists of intangible assets ($492.4 million), which are subject to impairment (e.g., $1,315.0 million goodwill impairment in 2022).
• Reliance on the management team and key employees, with risks from labor shortages and high employee turnover (experienced in 2025).
• Growth depends on identifying and developing new geographies, physician partners, payors, and patients; failure to execute these strategies could harm the business.
• Decreased growth in the number of patients and physician partners or services provided could harm financial results.
• Primary dependence on capitated reimbursement from third-party payors, leading to potential delays, uncertainties, and reductions in Medicare reimbursement rates (e.g., CMS's 2027 MA rate announcement projects a 0.09% average increase).
• Termination or non-renewal of Medicare Advantage (MA) contracts with health plans (four health plans accounted for 75% of 2025 revenue) could materially affect revenue.
• Dependence on affiliated professional entities and other providers to effectively manage the quality and cost of care.
• Reductions in the quality ratings of the health plans served could materially affect the business.
• Developments affecting spending by the healthcare industry could adversely affect revenue.
• Information technology system failures, security breaches, cyberattacks (e.g., April 2023 BEC scam), or other cybersecurity deficiencies could harm operations.
• Actual or perceived failures to comply with data protection, privacy, and security laws (e.g., HIPAA, CCPA, My Health My Data Act) could lead to penalties and reputational damage.
• Operating in a heavily regulated industry, with risks of fines, penalties, and operational changes if complex government laws (e.g., Anti-Kickback Statute, Stark Law, False Claims Act) are not adhered to.
• Arrangements with affiliated professional entities may be found to constitute improper rendering of medical services or fee splitting under state laws (e.g., Oregon Senate Bill 951).
• Inspections, reviews, audits, and investigations by federal and state government programs and contractors (e.g., June 2024 DOJ Civil Investigative Demand) could result in adverse findings.
• The impact of recent healthcare legislation (e.g., ACA, OBBBA 2025, MACRA, ACO REACH, ACO LEAD) is unknown and may adversely affect the business.
• The company's only significant asset is a minority economic interest (46% as of Dec 31, 2025) in P3 LLC, making it dependent on P3 LLC's distributions.
• Changes in laws and regulations related to AI Technologies could adversely affect products, services, and results of operations.
• Obligation to make potentially significant payments under the Tax Receivable Agreement (TRA).
• Foresight Sponsor Group, LLC and its affiliates are not limited in their ability to compete with the company, presenting potential conflicts of interest.
• Failure to satisfy California regulations related to financial solvency and operational performance (e.g., Medcore HP's non-compliance) could limit or terminate business in California.
• Failure to meet Nasdaq Capital Market continued listing requirements could result in delisting of securities.
• Failure to maintain effective internal control over financial reporting could have a material adverse effect.
• Anticipated benefits of recent and future acquisitions or dispositions may not be realized, disrupting operations.
• The dual-class structure may result in a lower or more volatile market price for Class A common stock.
• Delaware law and corporate governance provisions contain anti-takeover measures.
• Sales of substantial amounts of Class A common stock by stockholders could cause the price to fall.
• Warrants may have an adverse effect on the market price of Class A common stock, and redemption of public warrants could render them worthless.
• Warrants accounted for as liabilities, with changes in fair value potentially having a material effect on financial results.
• The business could be adversely impacted by climate change, extreme weather conditions, and natural disasters.
• Risk of securities litigation, which is expensive and could divert management attention.
• No current plans to pay cash dividends on Class A common stock.
• The market price and trading volume of Class A common stock and Public Warrants may be volatile and could decline significantly.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research, the price and trading volume of securities could decline.
• Operating as a public company incurs significantly increased costs and requires substantial management time.
• Results of operations and financial condition are subject to management's accounting judgments and estimates, as well as changes in accounting policies.
• Scrutiny of, and evolving expectations regarding, sustainability and environmental, social, and governance (ESG) matters could increase costs and harm reputation.

Future Outlook

The company expects to continue incurring net losses and generating negative cash flows from operations for the foreseeable future, necessitating additional funding in 2026. It is actively exploring debt financing, equity issuances, and asset sales. Operating expenses are projected to increase with business growth, although the company aims to achieve operating efficiencies and improve per-member-per-month revenue as members remain longer in its care model. The company anticipates participating in the new ACO LEAD program, succeeding ACO REACH, and expects further regulatory changes in healthcare spending and payment models.

Management Comments

• "Our management has performed an analysis of our ability to continue as a going concern and has identified substantial doubt about our ability to continue as a going concern."
• "We continue to explore raising additional capital through a combination of debt financing and equity issuances and sales of assets."
• "We believe we have significant growth opportunities available to us across existing and new markets, with less than 1% of the 544,000 PCPs in the U.S. currently included in our physician network."
• "We expect that our PMPM revenue will continue to improve the longer members participate in our care model as we better understand and assess their health status (acuity) and coordinate their medical care."
• "We expect our corporate, general and administrative expenses to increase in absolute dollars in the future as we continue to invest to support growth of our business, as well as due to the costs required to operate as a public company..."

Industry Context

StockSavvy.ai notes that P3 Health Partners operates in the rapidly evolving U.S. healthcare industry, specifically targeting the $1,118.0 billion Medicare market, with a core focus on the Medicare Advantage (MA) segment, which is projected to reach 64% penetration by 2035. The company's model addresses pain points like unsustainable costs (U.S. spent $5.3 trillion on healthcare in 2024, projected to grow 5.8% annually), PCP shortages, and sub-optimal care quality by promoting value-based care. The industry is characterized by a shift from fee-for-service to value-based models, increasing consolidation among payors, and evolving regulatory frameworks, including new AI technology regulations and CMS's transition to models like ACO LEAD.

Comparison to Industry Standards

• The company's reported net losses and 'going concern' warning are significantly below the financial stability and profitability standards expected of established healthcare companies.
• The decline in at-risk membership and capitated revenue contrasts with the overall growth trend in the Medicare Advantage market, which is projected to increase to 64% penetration by 2035.
• The company's physician retention rate of over 88% for 2025 suggests a relatively strong ability to retain its affiliated providers, which is a positive indicator in the competitive value-based care landscape, where physician engagement is crucial.
• The company's strategy of allowing physicians to maintain independence through an affiliate model differentiates it from some competitors who acquire practices, aligning with a segment of the market that values autonomy, as indicated by the American Medical Association's report on physician-owned practices.
• The high interest rates (13.5% to 19.5%) on the company's unsecured promissory notes are substantially higher than typical corporate borrowing rates, reflecting significant perceived financial risk compared to more stable industry players.

Management Changes

Corporate Governance

Legal Proceedings

• The company received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) in June 2024 under the False Claims Act, investigating arrangements with insurance agents and brokers. The company is cooperating.
• Medcore HP, a licensed health plan acquired by the company, was determined by the California Department of Managed Health Care (DMHC) to be non-compliant with the positive tangible net equity requirement as of December 31, 2025, and was required to develop and implement a corrective action plan.
• In August 2024, the California DMHC imposed an administrative penalty of $150,000 and a corrective action plan on Medcore HP for failure to meet minimum tangible net equity levels and for untimely filing of certain annual reports and monthly financial statements.

Related Party Transactions

• The company received $18.0 million from a related party financing transaction in January and February 2026.
• The Florida Assets were sold on November 30, 2024, to entities affiliated with Chicago Pacific Founders (CPF), the company's principal stockholder.
• The company issued unsecured promissory notes (VGS 1, VGS 2, VGS 3, VGS 4, VGS 5) to VBC Growth SPV LLC entities, which are managed by CPF and whose equity holders include members of the company's Board of Directors and Chief Medical Officer.
• The company has a master services agreement with Allymar Health Solutions, an entity in which CPF has an ownership interest, incurring $9.9 million in service expenses in 2025 (up from $2.7 million in 2024).
• A master services agreement with Anderson Family LLC, another CPF equity investment, resulted in $0.3 million in service expenses in 2025.
• The company has a full-risk capitation agreement with Atrio Health Plans, also a CPF equity investment, which accounted for $223.4 million in capitated revenue in 2025 (down from $303.6 million in 2024).
• The CPF Letter Agreement, amended multiple times, outlines certain board designation rights, information rights, and a standstill restriction for CPF Parties, with the latest extension to January 1, 2026.
• The company formed P3 Commonwealth Innovation MSO, LLC with Commonwealth Primary Care ACO, LLC (CPC ACO), where P3 ACO holds an 80% membership interest and controls the board. P3 LLC is obligated to fund working capital needs and assume CPC ACO's CMS and CMMI obligations.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity raises, the possibility of delisting from Nasdaq, and continued volatility in stock price. No cash dividends are planned for the foreseeable future. The dual-class structure may also affect market perception and index inclusion.
• **Employees**: Experienced labor shortages and high employee turnover in 2025, which could impact operational stability and growth. Equity incentive awards may be less attractive due to stock price volatility.
• **Customers (Patients/Members)**: The company's focus on value-based care aims to improve clinical outcomes and provide personalized care. However, strategic termination of underperforming contracts could disrupt care for some members.
• **Payors**: The company's dependence on a concentrated number of payors (four health plans accounted for 75% of 2025 revenue) creates a risk of revenue loss if contracts are terminated or not renewed. Changes in Medicare Advantage reimbursement rates directly impact the company's financial viability.
• **Creditors**: Face substantial risk due to the 'going concern' warning, high outstanding indebtedness ($336.7 million), and a significant working capital deficit. While waivers were granted for debt covenant non-compliance related to the going concern opinion, future breaches remain a risk.

Next Steps

• Develop and implement a corrective action plan for Medcore HP's non-compliance with California's tangible net equity requirement.
• Regain compliance with Nasdaq listing rules by May 20, 2026, to avoid delisting.
• Continue exploring additional capital raising through debt, equity, and asset sales.
• CMS is expected to issue its 2027 Medicare Advantage Rate Announcement in the second quarter of 2026.
• CMS is expected to begin issuing payment year 2018 Risk Adjustment Data Validation (RADV) audit findings in mid-calendar year 2026.
• The company expects to participate in the ACO LEAD program, which is scheduled to operate from January 1, 2027, through December 31, 2036.
• More details regarding the ACO LEAD program, including CMS's selection of participating ACOs, are expected throughout 2026.
• The P3 Commonwealth Innovation MSO, LLC is required to have its initial budget for the 2026 Performance Year approved by the Board and each Member no later than March 31, 2026.
• The company will provide clinical, operational, and data-driven support to primary care providers in a Nebraska Medicare Advantage network, with a global risk agreement commencing in 2028.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by recurring net losses, a significant accumulated deficit, negative cash flows from operations, and an explicit 'substantial doubt about its ability to continue as a going concern' from management and auditors. Revenue and at-risk membership declined year-over-year, and while the company is actively seeking capital, the terms of its existing debt are already high-interest and complex. The Nasdaq delisting risk further compounds investor uncertainty. These factors indicate a highly precarious financial position with significant downside risk for investors.

Keywords

Medicare Advantage, Value-Based Care, Population Health Management, SEC Filing, 10-K, Financial Performance, Net Loss, Going Concern, Nasdaq Delisting, Debt Financing, Healthcare Regulation, Risk Adjustment, Capitation, Physician Network, Cybersecurity, Data Privacy, ACO REACH, ACO LEAD, P3 Health Partners